Localized pruritus
Conditions
Interventions
Experimental group:3% polidocanol emulsion
Negative control group:Silicon E Emulsion
Positive control group:Cyproheptadine Cream
Sponsors
Peking Union Medical College Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients with clinically confirmed localized pruritus of the skin; 2. Aged between 18 and 80 years old; 3. The subjects fully understand the content of this study and voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Individuals allergic to polidocanol, urea, cyproheptadine, or other excipient ingredients. 2. Patients with facial and scalp itching. 3. Patients with a clear diagnosis of chronic eczema, atopic dermatitis, lichen planus, psoriasis, or other skin diseases often accompanied by itching. 4. Patients with a clear diagnosis of systemic diseases that may induce itching, such as end-stage renal disease, primary biliary cirrhosis, cutaneous T-cell lymphoma, polycythemia vera, or lympho-hematopoietic system diseases. 5. Patients with chronic urticaria whose skin symptoms are not well controlled. 6. Those with obvious papules, blisters, lichenification, or nodular skin lesions at affected areas, or when itchy areas involve more than 10% of the body surface area. 7. Those with local skin exudation, ulceration, or secondary infection. 8. Individuals with a history of glaucoma or benign prostatic hyperplasia. 9. Pregnant or lactating women, and women planning to conceive during the study period. 10. Individuals who have regularly used topical corticosteroids or taken oral antihistamines within the past week. 11. Individuals who have used other oral or topical anti-itch medications concurrently within the past week. 12. Situations that may affect patient compliance, such as long-term business travel or vacations, drug addiction, or presence of mental illness. 13. Individuals determined by the investigator as unsuitable for inclusion in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The percentage of patients with a reduction of 30% or more in VAS score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Assessment of the Dermatology Life Quality Index (DLQI) questionnaire for patients;The duration of the patient's relief from itching;The time required for the patient's VAS score to decrease by 50%; | — |
Countries
China
Contacts
Public ContactShu Chang
Peking Union Medical College Hospital
Outcome results
None listed